This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-20. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
C2 photosynthesis (also called glycine shuttle and photorespiratory CO2 pump) is a CCM that works by making use of – as opposed to avoiding – photorespiration. It performs carbon refixation by delaying the breakdown of photorespired glycine, so that the molecule is shuttled from the mesophyll into the bundle sheath. Once there, the glycine is decarboxylated in mitochondria as usual, releasing CO2 and concentrating it to triple the usual concentration. Although C2 photosynthesis is traditionally understood as an intermediate step between C3 and C4, a wide variety of plant lineages do end up in the C2 stage without further evolving, showing that it is an evolutionary steady state of its own. C2 may be easier to engineer into crops, as the phenotype requires fewer anatomical changes to produce.
== Malignant neoplasm of bone, connective tissue, skin, and breast (170–175) == 170 Malignant neoplasm of bone and articular cartilage 170.9 Malignant neoplasm of bone and articular cartilage, site unspecified Ewing's sarcoma Osteosarcoma Chondrosarcoma 171 Malignant neoplasm of connective and other soft tissue Rhabdomyosarcoma 172 Malignant melanoma of skin 173 Other malignant neoplasm of skin 174 Malignant neoplasm of female breast 175 Malignant neoplasm of male breast
=== Whey-protein beverages === Whey-protein beverages were central to these technological developments that began in 1969, and Malaspina played a seminal role in their early commercialization. His approach to the Dairy Board concerned soluble whey protein specifically for carbonated acidic beverages, and he continued to press for sufficient quantities for market testing as Coca-Cola and the New Zealand industry developed beverage-grade whey protein concentrate. Coca-Cola also installed an ultrafiltration pilot plant in Brazil specifically to produce whey protein concentrate. That development program led to Tai, a whey-fortified, orange-flavored carbonated beverage launched by Coca-Cola in Brazil in 1971. Malaspina's nutritional beverage program subsequently led to Sansón, a pasteurized whey-protein beverage marketed by Coca-Cola in Mexico. These early products anticipated the much broader use of whey protein in nutritional beverages. By the late 1980s, whey proteins were gaining commercial importance in sports nutrition, weight management, and medical nutrition, with sports and nutritional beverages becoming significant applications for whey protein concentrate and, later, for whey protein isolate. Improvements in membrane filtration, diafiltration, and protein fractionation now enable manufacturers to produce whey ingredients with higher protein concentrations, improved solubility, and other properties tailored to different beverage formulations.
Extinct dinosaurs, as well as modern birds, include genera that are herbivorous and others carnivorous, including seed-eaters, fish-eaters, insectivores, and omnivores. While dinosaurs were ancestrally bipedal (as are all modern birds), some evolved into quadrupeds, and others, such as Anchisaurus and Iguanodon, could walk as easily on two or four legs. Cranial modifications like horns and crests are common dinosaurian traits, and some extinct species had bony armor. Although the best-known genera are remarkable for their large size, many Mesozoic dinosaurs were human-sized or smaller, and modern birds are generally small in size. Dinosaurs today inhabit every continent, and fossils show that they had achieved global distribution by the Early Jurassic epoch at latest. Modern birds inhabit most available habitats, from terrestrial to marine, and there is evidence that some non-avian dinosaurs (such as Microraptor) could fly or at least glide, and others, such as spinosaurids, had semiaquatic habits.
Sources: en.wikipedia.org
== History == The band was launched by vocalist Thomas Anselmi and guitarist Christian Thorvaldson, former members of the short-lived and controversial band Slow, with new bassist Eric Marxsen and drummer Pete Bourne. The band was formed in 1987, when Anselmi and Thorvaldson settled on that name after having collaborated under the short-lived band names Mo and Christian Thorvaldson's Freeze-Dried Dog since the demise of Slow. Initially, the band spelled its name as the symbol ©, pronounced as "Circle C". Under that name, they released a self-titled debut album via Geffen Records in 1991. That album sold poorly, and the band was dropped from Geffen. After a few years of struggling to continue in the music industry, they were signed to BMG Music, releasing their second album Love Story in 1996 under the name Copyright. The singles "Transfiguration" and "Radio" were released from that album. Love Story was a shortlisted Juno Award nominee for Best Alternative Album at the Juno Awards of 1998. The album The Hidden World followed in 2001, with the song "Rock Machine" being released as a single. The band disbanded not long after.
If there is no hypoglycemia at the time of the symptoms, this condition is called idiopathic postprandial syndrome. It might be an "adrenergic postprandial syndrome" — blood glucose levels are normal, but the symptoms are caused through autonomic adrenergic counterregulation. Often, this syndrome is associated with emotional distress and anxious behaviour of the patient. This is often seen in dysautonomic disorders as well. Dietary recommendations for reactive hypoglycemia can help to relieve symptoms of postprandial syndrome.
In fact, penicillin is soluble in ethanol, ether and chloroform. Further research was undertaken in the early 1930s by others including Harold Raistrick who confirmed the chemical instability of penicillin in 1932. While Fleming continued to send samples of the mould to researchers, the requests for samples tapered off.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.